Detection of residual tissue after thyroidectomy for papillary or follicular thyroid carcinoma
may be performed using diagnostic imaging with either 123I or 131I. The former is often …

Background In the management of patients with differentiated thyroid carcinoma, direct
comparison of the presence of scintigraphic stunning after a diagnostic dose of 131 I with …

Differentiated thyroid cancer is treated by (near) total thyroidectomy followed by radioiodine
(131 I) ablation of the residual active tissue in the thyroid bed. Controversy remains …

The use of 131I in doses of several mCi for scans can stun the thyrocytes and thyroid cancer
cells, whereas the usual dose (300 μCi) of 123I does not. We compared the diagnostic …

" Thyroid stunning" from diagnostic iodine-131 imaging prior to ablative therapy with 131 I for
well-differentiated thyroid carcinoma has been well reported, but documentation of the effect …

The aims of this study were to evaluate the efficacy of an empirically determined 'fixed'high
ablative dose of radioiodine (131 I) therapy and to determine the utility of ultrasonography …

Background Most patients with differentiated thyroid cancer are treated with radioiodine (131-
I) after thyroidectomy. The characteristics predictive of successful remnant ablation with low …

PURPOSE: The optimal dose of I131 for ablation of functioning residual thyroid tissue after
surgery is controversial. The current study was conducted to determine the optimal dose of …

Purpose This article examines the outcome of radioactive iodine ablation therapy for thyroid
cancer in high-risk patients and investigates background factors influencing ablation failure …

BACKGROUND Radioiodine has been used for more than a half‐century to ablate thyroid
remnants following thyroid surgery, but a single optimal dose has not been established. We …